These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11651 related articles for article (PubMed ID: 11122823)

  • 1. Melanoma peptide vaccines: from preclinical background to clinical trials.
    Weber J
    Curr Oncol Rep; 2000 Jan; 2(1):38-47. PubMed ID: 11122823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide vaccines for cancer.
    Weber J
    Cancer Invest; 2002; 20(2):208-21. PubMed ID: 11901542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
    Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
    Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma vaccines: prim and proper presentation.
    Timmerman JM; Levy R
    Nat Med; 1998 Mar; 4(3):269-70. PubMed ID: 9500593
    [No Abstract]   [Full Text] [Related]  

  • 5. Peptide vaccine trials for melanoma: preclinical background and clinical results.
    Talebi T; Weber JS
    Semin Cancer Biol; 2003 Dec; 13(6):431-8. PubMed ID: 15001162
    [No Abstract]   [Full Text] [Related]  

  • 6. Melanoma vaccines.
    Chapman PB
    Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines and melanoma.
    Nestle FO
    Clin Exp Dermatol; 2002 Oct; 27(7):597-601. PubMed ID: 12464156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination for malignant melanoma: recent developments.
    Jäger D; Jäger E; Knuth A
    Oncology; 2001; 60(1):1-7. PubMed ID: 11150901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Closing in on a melanoma skin cancer vaccine.
    Mayo Clin Health Lett; 2012 Oct; 30(10):4. PubMed ID: 23133855
    [No Abstract]   [Full Text] [Related]  

  • 10. Melanoma antigens and targets for vaccination.
    Kang N; Truman H; Sanders R; Kupsch J
    Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-based cancer vaccines.
    Machiels JP; van Baren N; Marchand M
    Semin Oncol; 2002 Oct; 29(5):494-502. PubMed ID: 12407514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma vaccines.
    Elliott B; Dalgleish A
    Hosp Med; 2004 Nov; 65(11):668-73. PubMed ID: 15566059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination.
    Chen Q; Jackson H; Shackleton M; Parente P; Hopkins W; Sturrock S; MacGregor D; Maraskovsky E; Tai TY; Dimopoulos N; Masterman KA; Luke T; Davis ID; Chen W; Cebon J
    Cancer Immun; 2005 Mar; 5():5. PubMed ID: 15755075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines against advanced melanoma.
    Blanchard T; Srivastava PK; Duan F
    Clin Dermatol; 2013; 31(2):179-90. PubMed ID: 23438381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
    Slingluff CL; Petroni GR; Olson W; Czarkowski A; Grosh WW; Smolkin M; Chianese-Bullock KA; Neese PY; Deacon DH; Nail C; Merrill P; Fink R; Patterson JW; Rehm PK
    J Clin Oncol; 2008 Oct; 26(30):4973-80. PubMed ID: 18809608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials.
    Melssen MM; Pollack KE; Meneveau MO; Smolkin ME; Pinczewski J; Koeppel AF; Turner SD; Sol-Church K; Hickman A; Deacon DH; Petroni GR; Slingluff CL
    Cancer Immunol Immunother; 2021 Aug; 70(8):2151-2164. PubMed ID: 33454795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines for melanoma. Design strategies and clinical results.
    Bystryn JC
    Dermatol Clin; 1998 Apr; 16(2):269-75. PubMed ID: 9589200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 583.